Compare Enveric Biosciences Inc (ENVB) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs NEOS S&P 500 High Income ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while NEOS S&P 500 High Income ETF trades at $54.02 (market cap $12.51B). The key difference: NEOS S&P 500 High Income ETF is far larger — about 1870× Enveric Biosciences Inc's market cap, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and NEOS S&P 500 High Income ETF for 57 Days on average.
| ENVB | SPYI | |
|---|---|---|
Market Cap | $6.69M | $12.51B |
Volume | 41,141 | 2,751,602 |
Sector | Health | Income / Options Overlay |
52-Week High | $10.80 | $54.42 |
52-Week Low | $1.27 | $47.98 |
Typical Hold Time | 14 Days | 57 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
SPYI trades at $54.01, down 0.13% with a bullish technical signal from moving averages. The ETF shows strong institutional interest as a covered-call income vehicle, though recent news highlights concerns about principal erosion from high-yield strategies. Technical indicators show RSI at overbought levels while support and resistance cluster around $54.
The outlook remains mixed with strong income generation potential offset by capital preservation risks. Recent coverage emphasizes the trade-off between high monthly distributions and potential long-term principal decline, requiring careful consideration for retirement income strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
